A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer

Hunan Province Tumor Hospital

Status: Enrolling

Conditions: Advanced Lung Cancer

Treatments: Other: No treatment is included in this protocol.

Study type: Observational

Funder types: Other

Identifiers

NCT06183762

MET RWS

Details and patient eligibility

About

This is a descriptive observational study in which data are collected in an epidemiological manner. This study is not intended to alter or interfere with the current medical practice of the enrolled patients. Data will be collected in a forward-looking manner. This is a descriptive observational study in which data are collected in an epidemiological manner. This study is not intended to alter or interfere with the current medical practice of the enrolled patients. Data from patients on prior treatment will be collected retrospectively, and data from patients who will be treated later and included in the study will be collected in a prospective manner. The criteria for retrospective collection were consistent with those for prospective collection. Eligible patients will be enrolled after NGS analysis of tumor tissue and informed consent has been obtained. Information required for the study will be collected (every 3 months).

Enrollment: 200 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients must be ≥18 years of age.
2. Provision of fully informed consent prior to any study specific procedures.
3. Histologically or cytologically confirmed, unresectable stage IIIB/IIIC or stage IV NSCLC.
4. Genetic variants of tumor tissue detected by NGS.

Exclusion criteria

None.

Trial design

200 participants in 4 patient groups

ICIs

Description:

Patients receiving in first-line immunotherapy with or without anti-angiogenic or chemotherapy

Treatment:

Other: No treatment is included in this protocol.

Savolitinib

Description:

Patients receiving in first-line savolitinib treatment

Treatment:

Other: No treatment is included in this protocol.

Glumetinib

Description:

Patients receiving in first-line glumetinib treatment

Treatment:

Other: No treatment is included in this protocol.

Bozitinib

Description:

Patients receiving in first-line bozitinib treatment

Treatment:

Other: No treatment is included in this protocol.